Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:


1/12/2015 Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
…Hemispherx Reports Ampligen® Improves Function of NK Cells Obtained from CFS Patients

1/9/2015 Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma

12/16/2014 Hemispherx’s Ampligen® Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
…Positive Effects Reported in a Melanoma Model

12/9/2014 Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen® Enlarged by Howard University Research
… Independent Demonstration of Anti-Ebola Function of Hemispherx’s Biotherapeutic

11/17/2014 Ampligen® Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality in Man
… European University Report Establishes that VP35 Binding by Ampligen® May Restore Ability to Activate Effective Immune Response and Thereby Survive Infection

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP


Investor Relations:

Charles Jones
CJones & Associates Public Relations